No one can summarize our work and that of others quite like Arndt.

At #ASCO25 yesterday, we shared results from the largest study to date evaluating ctDNA in #ColonCancer, highlighting the power of our Guardant Reveal™ test to inform critical treatment decisions.

#ASCO25 Checkpoint inhibitors rarely move the needle alone in MSS CRC—but with vilastobart (XTX101), that may be changing. 🧬 Tumor-activated, Fc-enhanced anti-CTLA-4 ➕ Atezolizumab in late-line, checkpoint-naïve MSS CRC (N=40) 💥 In NLM patients (n=11): 2 confirmed + 1

Enjoying interacting with other speakers and discussants during today’s plenary. Exciting new data was presented.

Don’t let your patients overlook the least toxic and costly intervention to improve outcome.

Have a look…

Enjoyed crossing paths with long term friends and colleagues including new Editor of Clinical Colorectal Cancer (SG)

For dMMR colon cancer, FOLFOX + atezolizumab per ATOMIC is now incorporated into the NCCN Guidelines. Mayo Clinic Comprehensive Cancer Center Alliance for Clinical Trials in Oncology The ASCO Post Colorectal Cancer Alliance Cure GI Cancers Fight Colorectal Cancer

Hot off the press and pleased to collaborate on this important study. Patterns in genomic mutations among patients with early-onset colorect... sciencedirect.com/science/articl… Mayo Clinic Comprehensive Cancer Center Cure GI Cancers Colorectal Cancer Alliance Fight Colorectal Cancer Mayo Clinic Gastroenterology & Hepatology

Enjoyed ESMO GI 2025 in Barcelona. Gave update on blood based tests for cancer screening.

Potential mechanism underlying ability of exercise to enhance immune response against cancer

Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study - The Lancet Oncology thelancet.com/journals/lanon…

Enjoyed providing an update on blood-based cancer screening tests including for CRC at ESMO GI. Mayo Clinic Comprehensive Cancer Center Mayo Clinic Gastroenterology & Hepatology ASCO AACR American Gastroenterological Association (AGA)

Implications of BRAF V600E in dMMR/MSI-H pts treated with ICIs. Prognostic impact of the BRAF V600E mutation in patients with MSI-high... sciencedirect.com/science/articl… AACR Journal of Clinical Oncology ASCO Mayo Clinic Comprehensive Cancer Center

Neoadjuvant therapy-induced pCR not a surrogate for survival. Pathologic Complete Response and Survival in Rectal Cancer jamanetwork.com/journals/jaman…

Proud and honored to have my son, Anthony, join class of 2029 at U Colorado SOM.

Evolving crisis in academic oncology

Check out our new publication on the use of a CDK2/9 inhibitor for treatment of BRAF mutant colorectal cancer. rdcu.be/ezzYF Mayo Clinic Comprehensive Cancer Center Mayo Clinic AACR @asco Fight Colorectal Cancer Colorectal Cancer Alliance American Gastroenterological Association (AGA) Mayo Clinic Gastroenterology & Hepatology

🔥off the press, now fully published Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Annals of Oncology doi.org/10.1016/j.anno… 😅all you need to know! ESMO - Eur. Oncology

OHSU receives 2 billion gift !! Great to see captains of industry generously support cancer research!